Login to Your Account

33 skidoo as Anaptysbio exiting I.V. for subcu in eczema bid

By Randy Osborne
Staff Writer

Tuesday, October 10, 2017

Anaptysbio Inc.'s phase IIa interim data win with intravenous (I.V.) ANB-020, the antibody targeting interleukin-33 (IL-33) for eczema, touched off speculation about competitors working in the same pathway, as the firm's shares climbed 101 percent to close Tuesday at $70.41.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription